Download Files:
Vorapaxar
SKU
HY-10119-1 mg
Category Reference compound
Tags Cardiovascular Disease, GPCR/G Protein, Protease Activated Receptor (PAR)
$88 – $750
Products Details
Product Description
– Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner[1].
Web ID
– HY-10119
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C29H33FN2O4
References
– [1]Khoufache K, et al. PAR1 contributes to influenza A virus pathogenicity in mice. J Clin Invest. 2013 Jan;123(1):206-14.|[2]Kehinde O, et al. Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction. J Pharm Bioallied Sci. 2016 Apr-Jun;8(2):98-105.
CAS Number
– 618385-01-6
Molecular Weight
– 492.58
Compound Purity
– 99.85
SMILES
– O=C(O[C@@H]1C)[C@@]2([H])[C@]1([H])[C@@H](/C=C/C3=NC=C(C=C3)C4=CC=CC(F)=C4)[C@]([C@](C5)([H])C2)([H])CC[C@H]5NC(OCC)=O
Clinical Information
– Launched
Research Area
– Cardiovascular Disease
Solubility
– DMSO : 25 mg/mL (ultrasonic)
Target
– Protease Activated Receptor (PAR)
Isoform
– PAR1
Pathway
– GPCR/G Protein
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.